Skip to main content

Ashvattha Therapeutics to Participate in Upcoming Investor Conferences

Written by Customer Service on . Posted in Earnings Releases And Operating Results.

REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) — Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells in regions of inflammation, today announced that members of its senior management team will participate in two upcoming investor conferences.

Conference Details:

BIO CEO & Investor Conference

Format: Corporate Presentation
Date: Tuesday, February 27, 2024
Time: 11:45 – Noon ET
Location: The New York Marriott Marquis

Ashvattha’s Co-Founder and Chief Executive Officer, Jeffrey Cleland, Ph.D., and Chief Financial Officer, Paul Cayer, will be available for one-on-one meetings. If you are interested in a meeting, please reach out via the BIO One-on-One Partnering system.

Evercore ISI 2024 Emerging Biotech Conference

Format: Fireside Chat
Date: Thursday, February 29, 2024
Time: 11:20 – 11:50 am ET
Location: Virtual

Members of Ashvattha’s management team will provide an update on the company’s multiple Phase 2 clinical trials and upcoming data readouts.

About Ashvattha Therapeutics 
Ashvattha Therapeutics is advancing a new class of clinical-stage nanomedicine therapeutics that traverse tissue barriers to selectively target activated cells only in regions of inflammation. Our targeted nanomedicine approach seeks to redefine precision medicine, empowering a new standard of care across ophthalmology, neurology, and inflammation. For more information, visit: www.avttx.com

Media Contact
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
628-234-3889

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.